| 價格 | ¥238 | ¥592 | ¥788 |
| 包裝 | 1mg | 5mg | 10mg |
| 最小起訂量 | 1mg |
| 發(fā)貨地 | 上海 |
| 更新日期 | 2026-06-29 |
| 中文名稱:化合物 WAY-262611 | 英文名稱:WAY-262611 |
| CAS:1123231-07-1 | 品牌: TargetMol |
| 產地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 純度規(guī)格: 99.09% | 產品類別: 抑制劑 |
| 貨號: T1971 |
| 名稱 | WAY-262611 |
| 描述 | WAY262611 is a Wnt/β-catenin agonist and an inhibitor of Dkk1. It increases bone formation rate with EC50 of 0.63 μM in TCF-luciferase assay. |
| 激酶實驗 | PI3K and mTOR kinase assay : Enzyme assays are done in fluorescent polarization (FP) format, adapted from the Echelon K-1100 PI3K FP assay kit protocol. Human class I PI3Ks and PI3K-α mutants (E545K and H1047R) are produced in Sf9 or purchased from Upstate Biotech. GST-GRP1 (murine) is produced in Escherichia coli and isolated by GST-Sepharose. Assay buffers are reaction buffer [20 mM HEPES (pH 7.1), 2 mM MgCl2, 0.05% CHAPS, and 0.01% β-mercaptoethanol] and stop/detection buffer [100 mM HEPES (pH 7.5), 4 mM EDTA, 0.05% CHAPS]. FP reaction is run for 30 minutes at room temperature in 20 μL of reaction buffer containing 20 μM phosphatidylinositol 4,5-bisphosphate (PIP2), 25 μM ATP, and <4% DMSO. FP reaction is stopped with 20 μL of stop/detection buffer (10 nM probe and 40 nM GST-GRP), and after 2 hours, data are collected using an Envision plate reader. The routine assays with purified FLAG-TOR (FL and 3.5) are performed in 96-well plates as follows. Enzymes are first diluted in kinase assay buffer (10 mM Hepes (pH 7.4), 50 mM NaCl, 50 mM β-glycerophosphate, 10 mM MnCl2, 0.5 mM DTT, 0.25 μM microcystin LR, and 100 μg/mL BSA). To each well, 12 μL of the diluted enzyme is mixed briefly with 0.5 μL test inhibitor or control vehicle dimethyl sulfoxide (DMSO). The kinase reaction is initiated by adding 12.5 μL kinase assay buffer containing ATP and His6-S6K to give a final reaction volume of 25 μL containing 800 ng/mL FLAG-TOR, 100 μM ATP, and 1.25 μM His6-S6K. The reaction plate is incubated for 2 hours (linear at 1–6 hours) at room temperature with gentle shaking and then terminated by adding 25 μL Stop buffer (20 mM Hepes (pH 7.4), 20 mM EDTA, and 20 mM EGTA). |
| 體外活性 | WAY-262611在初級檢測中顯示出了最強的活性、較低的激酶抑制潛力和高溶解性[1]。 |
| 體內活性 | WAY-262611具有出色的藥代動力學特性,在劑量依賴的方式下,口服給藥后可顯著提高去卵巢大鼠的椎骨形成速率。采用WAY-262611處理的wt小鼠顱骨顯示,骨形成速率(BFR)統(tǒng)計上有顯著提升,但同樣處理的KO動物與對照組無明顯差異。這表明WAY-262611主要通過Wnt β-catenin途徑發(fā)揮作用,很可能通過抑制Dkk-1[1]來實現(xiàn)。 |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 41.67 mg/mL (130.86 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (3.14 mM), Sonication is recommended. |
| 關鍵字 | β-catenin | βcatenin | Wnt/β-catenin | Wnt/betacatenin | Wnt/b-catenin | Wnt | WAY-262611 | WAY262611 | WAY 262611 | Inhibitor | inhibit | beta-catenin | betacatenin | Beta catenin | bcatenin |
| 相關產品 | Urea | Nimbolide | Bisdemethoxycurcumin | Monensin sodium salt | Neohesperidin | XAV-939 | Isoquercetin | Chlorquinaldol | Methyl Vanillate | (±)-Nornicotine | Ethyl linoleate | Wnt pathway activator 1 |
| 相關庫 | 神經(jīng)保護化合物庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 抗結直腸癌化合物庫 | 成骨分子庫 | 抗卵巢癌化合物庫 | 血液病分子庫 | 膜蛋白靶向化合物庫 | 神經(jīng)元分化化合物庫 | Wnt/Hedgehog/Notch 通路化合物庫 | 抗前列腺癌化合物庫 |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 566.265100萬人民幣 |
| 員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 天然產物,生化試劑,分子生物學,分子砌塊,生物技術服務 | 經(jīng)營模式 | 貿易,工廠,試劑,定制,服務 |
| 產品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| ¥1098 |
VIP4年
|
上海滬震實業(yè)有限公司
|
2026-07-29 | |
| 詢價 |
VIP7年
|
上海澤葉生物科技有限公司
|
2026-07-29 | |
| 詢價 |
VIP11年
|
上海芮暉化工科技有限公司
|
2026-07-15 | |
| 詢價 |
VIP3年
|
北京百普賽斯生物科技股份有限公司
|
2026-06-30 | |
| ¥1670.90 |
VIP3年
|
上海阿拉丁生化科技股份有限公司
|
2026-06-10 | |
| 詢價 |
VIP1年
|
陜西締都醫(yī)藥有限責任公司
|
2026-04-22 | |
| ¥1520 |
VIP1年
|
上海聯(lián)邁生物工程有限公司
|
2026-03-31 | |
| ¥1890 |
VIP2年
|
上海鈺博生物科技有限公司
|
2026-03-26 | |
| ¥1220 |
青島梁會計
|
2022-10-28 | ||
| 詢價 |
VIP6年
|
河南科銳化工有限公司
|
2022-10-28 |